Mirxes Completes $50 Million Series D to Accelerate Cancer Early-Screening Pipeline R&D and Commercialization

On July 27, leading RNA technology company Mirxes Holdings Limited (hereinafter referred to as Mirxes) announced the completion of its Series D funding round, raising $50 million in total. Investors include Fopu Capital, the Singapore Economic Development Board's dedicated investment fund (EDBI), a subsidiary of Singapore's Agency for Science, Technology and Research (A*STAR), Japan's Mitsui & Co., and New Horizon Ventures. Gaorong Ventures participated in Mirxes' Series B round in 2018.

The proceeds from this round will accelerate Mirxes' R&D pipeline for early cancer screening and strongly drive commercialization across key Asia-Pacific markets.

Founded in 2014, Mirxes is dedicated to providing innovative blood-based early cancer screening products and services globally. The company has developed and commercialized precise, non-invasive, and affordable blood miRNA detection assays for early screening of cancer and other diseases.

Among these, its gastric cancer screening product (GASTROClear™/觅小卫™) is a blood-based miRNA molecular diagnostic kit that has been approved in Singapore and received EU CE certification. It is currently undergoing a near-10,000-person prospective clinical trial in China. According to industry reports, Mirxes is the first and only company worldwide to obtain regulatory approval for a molecular gastric cancer screening in vitro diagnostic (IVD) product.

Additionally, Mirxes has launched its flagship initiative — the CADENCE (Cancer Detected Early caN be CurEd) project. Based on the company's industry-leading miRNA technology combined with multi-omics biomarker detection, it aims to develop a blood-based early screening test covering nine types of cancer.

Dr. Lihan Zhou, co-founder and CEO of Mirxes, stated: "Closing this new $50 million funding round in a challenging macro environment further demonstrates the significance of our industry-leading miRNA detection technology platform in addressing the clinical and socioeconomic burden of cancer, and continues to solidify Mirxes' leadership position in the global early cancer screening technology field. We are honored to have the support and trust of both existing and new investors. We will fully advance commercialization in key Asia-Pacific markets and continue to push forward in the field of blood-based multi-cancer early detection."

The new investment will primarily be used to increase the penetration and repeat usage rates of Mirxes' blood-based gastric cancer screening test in major Asia-Pacific markets including Southeast Asia, China, and Japan, and to accelerate the development and commercialization of Mirxes' mature clinical pipeline, including blood-based colorectal and lung cancer screening assays, as well as the CADENCE multi-cancer blood-based early detection test.

Going forward, the company will build an industry-leading multi-omics technology company centered on RNA technology, fully promote the commercialization of blood-based early cancer screening products in Asia-Pacific markets, and establish Southeast Asia's leading full-course cancer genetic testing platform to meet the enormous clinical demand in the region.

With solid capital reserves, an expanding market share, and support from both new and long-standing strategic partners, Mirxes is also fully prepared to advance its mission of making early disease detection accessible and convenient on a global scale, resolutely reducing the burden of cancer and lowering healthcare costs through innovative RNA testing for early disease detection, and creating a healthier future for the public.